Best Life Sciences Companies in Malvern, United States

VenatroRx is a US-based, clinical stage biotech developing beta-lactamase inhibitors for DR infections. The company focuses on beta-lactamase inhibitors that target penicillin binding proteins to overcome bacterial resistance to beta-lactam drugs. Their lead candidate, VNRX‐5133, is an intravenous beta‐lactamase inhibitor. VNRX‐5133 is designed to inhibit the four major classes of beta‐lactamase resistance enzymes, including metallo‐beta‐lactamases (MBL). VenatoRx plans to use the drug to inhibit bacterial resistance mechanisms, enabling a paired beta-lactam antibiotic to kill the microorganisms. The other candidate is VNRX‐7145, an orally bioavailable beta‐lactamase inhibitor that is in late preclinical testing. In Jul.2017, the company was awarded $9.4M from CARB-X (Combating Antibiotic-Resistant Bacteria Accelerator)

Developer of medical device to address postpartum hemorrhage of women. It offers KOKO device, is a catheter-based technology to encourage uterine contractions while removing excess blood to stop postpartum hemorrhaging.

Funding rounds

• Feb 2026Series B$8M
• Dec 2023Series A$6M
• Nov 2021Seed$2.5M

Founders & team

Skott GreenhalghCo-Founder & CEOJason KeiserCo-Founder & VP of OperationsMichael WallaceCo-Founder & Chief Technology Officer

Biopharmaceutical company empowering patients through therapeutic innovation in immuno-inflammatory conditions. This organization strives to translate scientific discovery into everyday victories, focusing on underserved conditions. They develop investigational drug candidates and conduct clinical trials, engaging in drug discovery and expanded access programs. Research and development efforts are supported by partnerships and investigator-initiated studies, with publications sharing their findings.

Developing innovative therapeutics targeting protein degradation for challenging diseases. The company is focused on advancing a new class of medicine through Molecular Glues and targeted protein degradation. Their platform leverages the ubiquitin system to develop therapies for challenging diseases, including neurodegenerative diseases like Parkinson’s and Alzheimer’s, cardiovascular disorders, metabolic dysfunction, and aging-related conditions. The company is engaged in drug discovery, delivering a pipeline of first-in-class therapeutics. They are exploring partnerships to further their reach and impact in the pharmaceutical industry. Their research focuses on areas like mitochondria, the Ubiquitin Proteasome System (UPS), and phospho-ubiquitin to restore mitochondrial functions and address diseases. The company is committed to innovation and redefining treatment paradigms through targeted protein degradation.

Funding rounds

• May 2025Grant (prize money)$302.4K
• 2024Grant (prize money)$269.6K
• 2022Grant (prize money)$551.5K
• 2021Grant (prize money)$266K

Founders & team

Tauseef ButtPresident and CEO

Investors

HHS, Ben Franklin Technology Partners

Tech stack

WordpressMysqlPhpDiviYoast SeoNginx

Developer of a medical device to treat valvular heart disease. The company has developed a "Leaflet Excision System" to target and excise one or more aortic valve leaflets and integrate them into the workflow of transcatheter aortic valve replacement procedures.

Funding rounds

• Sep 2024Series B$10.3M
• Dec 2023Series A$2M
• Mar 2023Series A$3M
• Dec 2022Seed$1.9M

Founders & team

David WoodCo-Founder

Manufacturer of foot and ankle fixation devices and plating systems. The company provides anatomically specific solutions for trauma and reconstruction. Products feature a low-profile design intended to minimize irritation and enhance mobility during recovery. The company's variable locking mechanism may eliminate screw migration, providing stability. The plating system combines a low-profile design with pathology-specific solutions tailored to the anatomy.

Funding rounds

• Dec 2025Seed$600K

Founders & team

Jeffrey O’Donnell Jr.CEO

Life science company providing innovative tools for ubiquitin proteasome system research. They are dedicated to advancing research through cutting-edge technologies and comprehensive solutions. They offer a wide array of products and services focused on protein degradation pathways, including PROTACs, molecular glues, TUBEs, ubiquitin ligases, deubiquitinating enzymes, and SUMOylation tools. Their offerings span from reagents and assays to custom solutions, supporting drug discovery and basic research. They provide tools for ubiquitination, protein expression, and analysis, catering to diverse research needs in areas like neurodegeneration, cancer, and therapeutic development. They also offer R&D services, including PROTAC development, DUB assays, and mass spectrometry proteomics. They are committed to enabling scientific breakthroughs through their innovative products and expert support.

Developer of meter-dosed spray & liposomal gels for topical pain management. The company is focusing on developing meter-dosed spray delivery for topical application of NSAIDs and an aerosol-based system that delivers API as a Patch-in-a-Can. Also, developing, local anesthetic liposomal gel, composed of encapsulated bupivacaine in hydrogel & lipids.

Developer of therapeutics for the treatment of cardiovascular disease. It works on the development of drugs for the treatment of cancer and cardiovascular diseases and the development of vaccine technology. The company develops drugs to lower bad cholesterol by targeting PCSK9 which eventually controls LDLR levels. The lead compound is P-21, an oral therapeutic that interferes with the function of PCSK9.

Transforming neurohealth with innovative, non-drug TMS therapy for mental health. The company is dedicated to improving the lives of individuals suffering from psychiatric disorders by offering patient-centric medical devices. They specialize in transcranial magnetic stimulation (TMS) treatment, providing a non-drug, non-invasive alternative for those with depression and OCD. Committed to practice success, they offer ongoing support and strive to expand their capabilities to cover additional indications. Their approach focuses on compassion, innovation, and growth, aiming to provide a safe, effective, and durable treatment option. They are committed to compliance and ethical practices, ensuring the highest quality of care for both patients and healthcare providers.

Developer of novel drugs to treat metabolic and cardiopulmonary disorders. The company has developed therapeutics by using elastin-like biopolymers which have been shown to increase drug half-life and bioavailability while reducing side effects and cost. The product portfolio includes Bentracimab an antiplatelet drug, Pemziviptadil for pulmonary arterial hypertension, PB6440 for hypertension.

Provider of a non-drug non-invasive therapeutic devices for neurorehabilitation. It focuses on the therapeutic applications of the MRI-strength pulsed magnetic field for treating disorders of the central nervous system. The TMS Therapy is an FDA cleared device used for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.